OakChart

Tonix Pharmaceuticals Holding Corp

TNXPHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.87-0.23 (-5.61%)
2026-11-12 03:42 CET
Market cap
66.37 USD m
Revenue, TTM
43.05 USD m
Net income, TTM
-180.99 USD m
Free cash flow, TTM
-168.30 USD m
EPS diluted, TTM
-12.24
P/E
-
Compare

Price

TNXP against its 20, 50 and 200-day averages
2050200beatmiss
5.0010.0015.0020.001.6M3.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TNXPclose 3.8720-day 5.1750-day 8.13200-day 11.953.8752w high

81.2% under the 52-week high of 20.56 on 12 Dec 2025. 52-week low 3.82 on 11 Nov 2026. Last 15 sessions, 44.2% high to low

Volume 4.61× normal · the line is the 50-bar volume average

Profile

TNXP
52-week range, 0% of the way up
4.0020.56

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

IndexRUT
Employees142
IPOFeb 03, 2012
Beta1.91
ATR, 14d0.46
Rel volume4.61
Insider own0.36%
Inst own57.58%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap75.20M
Enterprise Value-86.34M
Income-180.99M
Sales43.05M
Book/sh10.42
Cash/sh8.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees142
IPOFeb 03, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S1.75
P/B0.37
P/C0.46
P/FCF-
EV/EBITDA-
EV/Sales-2.01
Quick Ratio4.47
Current Ratio4.57
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-12.24
EPS next Y-6.18
EPS next Q-2.48
EPS this Y27.14%
EPS next Y41.83%
EPS next 5Y38.80%
EPS past 3/5Y93.94% 86.72%
Sales past 3/5Y- -
EPS Y/Y TTM98.76%
Sales Y/Y TTM317.96%
EPS Q/Q19.39%
Sales Q/Q423.83%
EarningsNov 09 BMO
EPS/Sales Surpr.-21.00% 5.62%

Ownership

Insider Own0.36%
Insider Trans30.46%
Inst Own57.58%
Inst Trans8.31%
ROA-73.15%
ROE-84.06%
ROIC-90.31%
Gross Margin83.98%
Oper. Margin-436.25%
Profit Margin-420.45%
SMA20-25.14%
SMA50-52.39%
SMA200-67.61%
Trades-

Technical

Shs Outstand19.15M
Shs Float-
Short Float-
Short Ratio4.81
Short Interest3.32M
52W High20.56 -81.18%
52W Low4.00 -3.25%
Volatility12.76% 8.56%
ATR (14)0.46
RSI (14)14.95
Beta1.91
Rel Volume4.61
Avg Volume689.72K
Volume3,176,488

Performance

Perf Week-24.27%
Perf Month-36.87%
Perf Quarter-69.04%
Perf Half Y-72.04%
Perf YTD-75.22%
Perf Year-77.92%
Perf 3Y-99.74%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price31.60
Prev Close4.10
Price3.87
Change %-5.61%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Oct 26, 2026InitiatedCCanaccord GenuityBuy$18+365.1%
Jun 25, 2026InitiatedRRaymond JamesStrong Buy$26+571.8%
May 04, 2026InitiatedTTD CowenBuy$22+468.5%
Apr 18, 2022InitiatedNNoble Capital MarketsOutperform
Apr 18, 2019UpgradeRROTH CapitalNeutral → Buy$4+3.4%
Aug 18, 2017UpgradeRROTH CapitalNeutral → Buy$6+55.0%
Sep 07, 2016DowngradeRROTH CapitalBuy → Neutral
Feb 17, 2016ReiteratedOOppenheimerOutperform$18 → $10+158.4%
Nov 04, 2015InitiatedCCantor FitzgeraldBuy
Jun 12, 2015InitiatedOOppenheimerOutperform$18+365.1%

Peers

Mkt cap
TickerCompanyMkt cap
VNDAVanda Pharmaceuticals Inc250.95M
AXSMAxsome Therapeutics Inc7.85B
DWTXDogwood Therapeutics Inc45.11M
RLMDRelmada Therapeutics Inc472.55M
HRMYHarmony Biosciences Holdings Inc2.01B
CINGCingulate Inc67.47M
MNOVMedicinova Inc69.40M
ANROAlto Neuroscience Inc1.22B
TRVITrevi Therapeutics Inc2.11B
VTGNVistagen Therapeutics Inc8.34M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
LEDERMAN SETHChief Executive OfficerAug 27 '26Buy13.792,00027,58011,005Aug 31 08:00 AM
BAGGER RICHARD HDirectorAug 20 '26Buy12.601,00012,6001,000Aug 24 08:00 AM
Taylor Carolyn E.DirectorJun 12 '26Buy10.551,41514,9281,833Jun 15 07:00 AM
Stillwell Richard NewcombDirectorJun 08 '26Buy11.655,00058,2505,000Jun 09 05:30 PM
LEDERMAN SETHChief Executive OfficerJun 09 '26Buy11.795,00058,9509,005Jun 09 05:30 PM
LEDERMAN SETHChief Executive OfficerMar 31 '26Buy12.625,00063,10020,001Apr 01 09:31 AM
LEDERMAN SETHChief Executive OfficerMar 18 '26Buy14.8915,000223,35015,001Mar 18 05:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200
  • Tonix Beats On Revenue But Misses On EPS As TONMYA Growth Slows Sharply And A Generic Challenge Arrives (Earnings Whispers) -5.27%
  • Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
  • Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference (GlobeNewswire)
  • Tonix Faces A Revenue Ramp Test As Shares Sink Near Post-Earnings Lows (Earnings Whispers)
  • Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation (GlobeNewswire)
  • Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain (GlobeNewswire)
  • Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 (GlobeNewswire)
  • Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA at the IASP 2026 World Congress on Pain (GlobeNewswire) -5.13%
  • Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026 (GlobeNewswire)
  • Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA (GlobeNewswire)
  • Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer (GlobeNewswire)
  • Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference (GlobeNewswire)
  • Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... (GuruFocus.com)
  • Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-2.890-2.389-2.89017.2316.325
2026Q22026-08-10-2.440-2.643-2.43813.547.724
2026Q12026-05-11-2.930-2.570-2.9326.886.134
2025Q42026-03-12-3.980-3.190-3.9765.392.973
2025Q32025-11-10-3.590-3.585-3.5873.292.302
2025Q22025-08-11-3.860-2.770-3.8592.002.433
2025Q12025-05-12-2.840-3.090-2.8392.432.601
2024Q42025-03-18-9.770-18.500-976.72.583.202
2024Q32024-11-12-23.000-388-22.8792.823.152
2024Q22024-08-19-1,928-327.33-1,9282.213.503
2024Q12024-05-13-576-880-591.072.483.852
2023Q42024-04-01-21,920-4,683-2,7537.775.173
2023Q32023-11-09-5,856-4,768-5,8403.995.803
2023Q22023-08-10-8,576-9,611-8,5710.000.003
2023Q12023-05-08-10,400-9,667-10,4190.000.003
2022Q42023-03-13-11,200-17,200-11,1060.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-12,371,200-9,952,000-12,370,5540.000.00
2020FY-352,000-304,000-353,0050.000.00
2021FY-166,400-156,800-163,9680.000.00
2022FY-65,400-77,467-65,4060.000.00
2023FY-2,752-26,784-21,9083.7810.33
2024FY-176.6-113.5-17,66010.0912.80
2025FY-14.570-13.430-14.57013.1110.43
2026FY--10.616--57.18
2027FY--6.175--112.81
2028FY--3.340--186.21
2029FY--2.147--253.13
2030FY--0.177--313

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0953220.3016.5023.00
2026Q4S2026-10-2652119.1216.5023.00
2026Q4S2026-10-2452119.1216.5023.00
2026Q4S2026-10-2353119.1216.5023.00
2026Q4S2026-10-2043118.7016.5023.00
2026Q4S2026-10-1943118.0816.0023.00
2026Q4S2026-09-0244018.8316.0026.00
2026Q4S2026-08-2833019.6016.0026.00
2026Q4S2026-08-1043017.159.8026.00
2026Q4S2026-07-2641010.587.9315.00
2026Q4S2026-07-2041110.587.9315.00
2026Q4S2026-06-2340110.527.9314.74
2026Q4S2026-06-213019.117.939.80
2026Q4S2026-05-2740111.067.9316.90

Estimate history

EPS, annual-202880000.001-57771776-12370553.6-353004.8-163968-65405.8-21908.48-17659.801-14.571-12.2378
Period201720182019202020212022202320242025TTM
EPS, quarterly-22.879-976.702-2.839-3.859-3.587-3.976-2.932-2.438-2.892
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000007.76810.09413.10743.05
Period201720182019202020212022202320242025TTM
Sales, quarterly2.8222.5822.4291.9983.295.396.87813.54417.234
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual00000.0010.0040.0180.04412.78819.15
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.5560.0446.8787.54610.16812.78814.20516.79219.15
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue43.0513.1110.097.770.000.000.000.000.00
Cost of Goods Sold Incl. D&A6.908.5711.199.031.250.050.030.030.05
Gross Profit36.154.54-1.09-1.26-1.25-0.05-0.03-0.03-0.05
Selling, General and Administrative Excl. Other223.94130.2576.65117.12110.8492.2650.4828.8026.27
Research and Development80.4044.4939.9786.6681.8868.8436.1618.1917.56
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-187.79-125.70-77.74-118.38-112.09-92.31-50.51-28.83-26.32
Interest Expense-0.09--0.000.000.000.000.00
Unusual Expense0.002.0952.81-0.300.000.00---
Net Income Before Taxes-180.99-124.02-130.04-116.66-110.22-92.29-50.46-28.62-26.09
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-180.99-124.02-130.04-116.66-110.22-92.29-50.46-28.62-26.09
Net Income From Continuing Operations-180.99-124.02-130.04-116.66-110.22-92.29-50.46-28.62-26.09
Net Income-180.99-124.02-130.04-116.66-116.88-92.29-52.17-31.09-29.36
EPS (Recurring)-9.81-14.40-12,639.71-21,947.93-65,405.75-163,967.71-353,005.12-12,370,555.67-57,771,750.66
EPS (Basic, Before Extraordinaries)-12.24-14.57-17,659.80-21,908.48-65,405.80-163,968.00-353,004.80-12,370,553.60-57,771,776.00
EPS (Diluted)-12.24-14.57-17,659.80-21,908.48-65,405.80-163,968.00-353,004.80-12,370,553.60-57,771,776.00
EBITDA-185.49-123.78-74.32-114.09-110.84-92.26-50.48-28.80-26.27
Non-Operating Income (Expense)6.813.860.521.421.870.030.050.210.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.306.004.809.308.615.772.451.46-
Price To Sales Ratio4.1710.140.020.88-----
Gross Margin83.9834.65-10.82-16.27-----
Operating Margin-436.25-959.05-770.20-1,523.94-----
Net Margin-420.45-946.22-1,288.25-1,501.78-----
Shares Outstanding19.1512.790.040.020.000.000.000.000.00
Market Capitalization66.3766.371.457.1620.78177.51139.069.987.15

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue17.2313.546.885.393.292.002.432.58
Cost of Goods Sold Incl. D&A1.901.322.131.551.833.761.441.68
Gross Profit15.3412.224.753.841.46-1.760.990.90
Selling, General and Administrative Excl. Other70.7754.7646.2852.1334.5326.5417.0523.38
Research and Development25.8219.4218.2116.949.2910.827.448.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-55.43-42.53-41.54-48.29-33.07-28.30-16.05-22.48
Interest Expense0.000.000.00--0.00--
Unusual Expense0.000.000.000.000.000.002.090.00
Net Income Before Taxes-53.33-40.55-40.19-46.91-32.01-28.27-16.83-22.11
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-53.33-40.55-40.19-46.91-32.01-28.27-16.83-22.11
Net Income From Continuing Operations-53.33-40.55-40.19-46.91-32.01-28.27-16.83-22.11
Net Income-53.33-40.55-40.19-46.91-32.01-28.27-16.83-22.11
EPS (Recurring)-2.89-2.44-2.93-3.98-3.59-3.86-2.59-976.70
EPS (Basic, Before Extraordinaries)-2.89-2.44-2.93-3.98-3.59-3.86-2.84-976.70
EPS (Diluted)-2.89-2.44-2.93-3.98-3.59-3.86-2.84-976.70
EBITDA-54.79-41.92-40.98-47.80-32.61-27.81-15.56-21.98
Non-Operating Income (Expense)2.101.981.341.381.060.021.320.37
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.202.301.901.901.801.400.900.90
Price To Sales Ratio4.177.2910.7414.0620.9326.8210.550.07
Gross Margin89.0090.2468.9971.3244.44-87.9440.8834.97
Operating Margin-321.64-314.05-603.91-895.84-1,005.08-1,416.22-660.93-870.64
Net Margin-309.44-299.41-584.38-870.32-972.95-1,415.02-692.84-856.24
Shares Outstanding19.1516.7914.2112.7910.177.556.880.04
Market Capitalization66.37203.40184.32183.95211.78264.71115.021.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments207.6498.7824.95120.23178.6677.0711.2525.0325.50
Short Term Receivables9.767.904.598.047.737.630.000.000.00
Inventories6.018.4114.150.000.000.000.000.000.00
Other Current Assets5.473.914.082.502.663.292.701.020.95
Total Current Assets228.88119.0047.77130.78189.0587.9913.9526.0626.44
Net Property, Plant & Equipment46.0042.8294.8594.5351.479.830.390.040.09
Total Investments and Advances2.170.900.900.240.240.240.100.100.09
Intangible Assets0.120.1210.71-0.120.120.120.120.12
Other Assets0.000.050.230.140.020.010.000.000.01
Total Assets277.17162.89154.46225.69240.9098.1814.5626.3226.75
Short Term Debt Incl. Current Port. of LT Debt0.123.092.620.430.490.590.350.000.00
Accounts Payable8.114.553.788.0713.284.603.071.401.30
Other Current Liabilities22.6010.6712.489.687.954.631.711.250.83
Total Current Liabilities30.8418.3118.8818.1821.729.825.132.652.13
Long Term Debt1.185.037.190.330.470.720.010.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Other Liabilities0.000.0022.860.000.000.000.000.000.01
Total Liabilities32.0223.3348.9318.5122.1810.545.142.652.14
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity245.15139.56105.53207.18218.7287.659.4223.6624.62
Total Shareholders Equity245.15139.56105.53207.18218.7287.659.4223.6624.62
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity245.15139.56105.53207.18218.7287.659.4223.6624.62
Total Liabilities & Stockholders Equity277.17162.89154.46225.69240.9098.1814.5626.3226.75
Book Value Per Share19.173,181.955,761.0254,180.35282,075.83272,292.99706,426.4446,571,647.34201,202,548.14
Tangible Book Value Per Share19.163,179.215,176.4354,180.35281,921.07271,920.19697,424.5146,335,482.80200,221,710.23
Full-Time Employees142811031175217161214
Price to Book Ratio0.370.010.060.090.811.591.060.300.91
Return on Assets-56.37-81.95-61.38-47.24-54.43-89.52-140.02-98.31-77.85
Return on Equity-64.48-106.12-74.61-51.76-60.25-103.98-173.02-108.07-84.53
Return on Invested Capital-50.35-89.94-103.50-53.11-42.10-57.11-303.70-110.25-85.81
Quick Ratio7.236.041.787.198.718.962.729.8112.44
Current Ratio7.426.502.537.198.718.962.729.8112.44

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-179.15-124.02-130.04-116.66-110.22-92.29-50.46-28.62-26.09
Depreciation2.271.933.424.291.250.050.030.030.05
Other Funds (Non Cash)7.4411.8759.9210.4010.9110.904.241.461.63
Funds from Operations-169.44-110.23-66.70-101.97-98.05-81.34-46.20-27.14-24.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.9010.385.78-0.04-0.005.78-2.370.450.44
Cash from Operating Activities-163.54-99.84-60.93-102.00-98.05-75.56-48.57-26.68-23.97
Capital Expenditures-4.75-3.37-0.12-7.90-48.15-35.31-8.56-0.02-0.01
Net Assets From Acquisitions0.000.000.00-22.170.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.001.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.02-2.010.000.000.000.000.000.000.00
Other Sources0.890.850.000.000.000.000.000.000.00
Cash from Investing Activities-3.84-4.53-0.12-29.07-48.15-35.31-8.56-0.02-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock139.81224.18140.2236.5287.84212.49123.1112.9223.54
Repurchase of Common Pref Stock-8.05-13.760.00-13.97-47.250.000.000.000.00
Sale of Common Pref Stock147.85237.94140.2250.48135.09212.49123.1112.9223.54
Proceedsfrom Stock Options80.040.000.0341.54135.090.00113.2112.8523.54
Issuance or Reduction of Debt, Net0.11-9.65-2.350.000.000.000.000.000.00
Change in Long Term Debt0.11-9.65-2.350.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.11-9.65-2.350.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-3.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-3.000.000.000.000.000.000.00
Cash from Financing Activities139.92214.53134.8736.5287.84212.49123.1112.9223.54
Exchange Rate Effect-0.11-0.030.00-0.07-0.07-0.03-0.02-0.00-0.01
Net Change in Cash-27.58110.1373.83-94.62-58.43101.5965.96-13.79-0.45
Free Cash Flow-168.30-103.21-61.05-109.90-146.20-110.86-57.13-26.70-23.98
Preferred Dividends (Cash Flow)-0.000.000.00-0.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments162.79176.23185.47207.64190.06125.33
Short Term Receivables19.0515.0512.219.766.067.87
Inventories4.484.683.656.015.735.99
Other Current Assets5.817.475.845.476.234.35
Total Current Assets192.13203.43207.17228.88208.07143.53
Net Property, Plant & Equipment46.1446.1146.3446.0042.9542.77
Total Investments and Advances2.562.562.712.171.290.90
Intangible Assets0.120.120.120.120.120.12
Other Assets1.481.871.580.000.010.03
Total Assets242.43254.09257.91277.17252.44187.36
Short Term Debt Incl. Current Port. of LT Debt0.340.250.160.120.160.20
Accounts Payable17.069.059.658.118.547.78
Other Current Liabilities24.6321.4819.8422.6012.3311.08
Total Current Liabilities42.0330.7929.6530.8421.0319.06
Long Term Debt0.921.021.131.180.270.30
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities42.9431.8130.7732.0221.3019.36
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity199.49222.28227.14245.15231.14168.00
Total Shareholders Equity199.49222.28227.14245.15231.14168.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity199.49222.28227.14245.15231.14168.00
Total Liabilities & Stockholders Equity242.43254.09257.91277.17252.44187.36
Book Value Per Share10.4213.2415.9919.1722.7322.26
Tangible Book Value Per Share10.4113.2315.9819.1622.7222.25
Full-Time Employees---142--
Price to Book Ratio0.370.800.720.691.091.37
Return on Assets-73.15-72.34-65.39-56.37-57.12-63.20
Return on Equity-84.06-81.82-72.33-64.48-64.99-77.51
Return on Invested Capital-26.61-18.16-17.61-19.04-13.83-16.80
Quick Ratio4.476.466.867.239.627.22
Current Ratio4.576.616.997.429.897.53

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-50.94-40.19-40.19-47.83-34.02-30.20
Depreciation0.610.610.560.490.490.52
Other Funds (Non Cash)2.182.241.971.062.335.91
Funds from Operations-48.15-37.34-37.67-46.28-31.19-23.77
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital9.28-4.53-4.655.800.687.59
Cash from Operating Activities-38.87-41.87-42.32-40.49-30.51-16.17
Capital Expenditures-0.55-0.58-1.69-1.93-1.02-0.55
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.02-0.02-2.10
Other Sources0.000.000.000.890.000.00
Cash from Investing Activities-0.55-0.58-1.69-1.02-1.03-2.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock26.8433.2720.2159.50100.2813.99
Repurchase of Common Pref Stock0.000.000.00-8.05-0.05-3.16
Sale of Common Pref Stock26.8433.2720.2167.54100.3317.15
Proceedsfrom Stock Options26.6633.1720.210.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.11-0.08-0.41
Change in Long Term Debt0.000.000.000.11-0.08-0.41
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.11-0.08-0.41
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities26.8433.2720.2159.61100.2013.58
Exchange Rate Effect-0.04-0.060.01-0.01-0.00-0.00
Net Change in Cash-12.63-9.24-23.8018.0968.65-5.25
Free Cash Flow-39.43-42.44-44.01-42.42-31.52-16.72

Revenue breakdown

Tonmya2025: 1.42M
Tosymra2024: 1.55M 2025: 2.37M
Zembrace Symtouch2024: 8.55M 2025: 9.31M
United States2024: 10.09M 2025: 13.11M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.42%3.3M17.1M653.04K
2026-10-1517.21%2.9M17.1M601.61K
2026-09-3017.19%2.9M17.1M476.61K
2026-09-1516.61%2.8M17.1M490.25K
2026-08-3118.15%3.1M17.1M534.41K
2026-08-1419.93%3.4M17.1M534.81K
2026-07-3122.66%3.6M15.9M526.17K
2026-07-1522.56%3.6M15.9M495.16K
2026-06-3022.54%3.6M15.9M488.54K
2026-06-1519.39%3.1M15.9M487.35K
2026-05-2918.02%2.9M15.9M435.41K
2026-05-1514.72%2.3M15.9M419.60K
2026-04-3018.40%2.6M14.2M394.30K
2026-04-1518.48%2.5M13.4M412.30K
2026-03-3115.49%2.1M13.4M416.30K
2026-03-1318.46%2.5M13.4M400.29K
2026-02-2716.46%2.1M12.8M448.73K
2026-02-1318.43%2.4M12.8M548.71K
2026-01-3018.26%2.3M12.8M598.80K
2026-01-1516.99%2.2M12.8M640.75K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.652.400.009.0300.000.000.927-0.0110.001
call5.000.000.100.051.6833119.000.199-0.0160.002
call7.500.002.450.053.10390.000.000.130-0.0220.001
call10.000.000.200.053.56192.000.000.109-0.0230.001
call12.500.001.000.024.0261170.000.060-0.0160.001
call15.000.004.900.104.6214.000.000.091-0.0260.001
call17.500.004.900.004.6070.000.000.051-0.0170.001
call20.000.004.900.004.9170.000.000.049-0.0180.001
call22.500.004.902.505.1994.000.000.047-0.0180.001
put2.500.004.900.102.1996.000.00-0.073-0.0100.001
put5.000.004.900.6529.5181030.00-0.801-0.0160.002
put7.501.005.102.249.41551.000.00-0.870-0.0220.001
put10.003.508.301.2313.6871.000.00-0.890-0.0240.001
put12.506.0010.907.1314.9273.000.00-0.940-0.0150.001
put15.008.5013.400.0015.4910.000.00-0.945-0.0150.001
put17.5011.0015.900.0015.9540.000.00-0.948-0.0160.001
put20.0013.5018.400.0016.3440.000.00-0.950-0.0160.001
put22.5016.0020.900.0016.6820.000.00-0.951-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-028-KCurrent report2026-10-01SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-083Initial statement of beneficial ownership of securities2026-09-04SEC
2026-08-314Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-188-KCurrent report2026-08-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13GSEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-218-KCurrent report2026-07-20SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-15SCHEDULE 13GSEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-088-KCurrent report2026-06-08SEC
2026-05-278-KCurrent report2026-05-27SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0840.18K200
2026-070000
2026-06132.13K300
2026-050000
2026-040000
2026-03286.45K200
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.77%
Point72 Asset Management, L.P.7.32%
MILLENNIUM MANAGEMENT LLC6.07%
AQR CAPITAL MANAGEMENT LLC5.54%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
Jones Hill Capital LP3.92%
GEODE CAPITAL MANAGEMENT, LLC2.48%
Ishara Investments LP2.12%
ESSEX INVESTMENT MANAGEMENT CO LLC1.70%
STATE STREET CORP1.70%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.06%
iShares Russell 2000 ETF2.45%
VANGUARD EXTENDED MARKET INDEX FUND1.18%
Fidelity Small Cap Index Fund1.00%
iShares Russell 2000 Value ETF0.91%
Fidelity Extended Market Index Fund0.54%
Fidelity Enhanced Small Cap Core ETF0.49%
VANGUARD RUSSELL 2000 INDEX FUND0.49%
1290 Essex Small Cap Growth Fund0.46%
College Retirement Equities Fund - Total Global Stock Account0.34%

OakChart. TNXP. Cached 15 minutes.